Matches in SemOpenAlex for { <https://semopenalex.org/work/W4214528097> ?p ?o ?g. }
- W4214528097 endingPage "1069" @default.
- W4214528097 startingPage "1069" @default.
- W4214528097 abstract "Glioblastoma multiforme (GBM), the most common and deadly brain cancer, exemplifies the paradigm that cancers grow with help from an immunosuppressive tumor microenvironment (TME). In general, TME includes a large contribution from various myeloid lineage-derived cell types, including (in the brain) altered pathogenic microglia as well as monocyte-macrophages (Macs), myeloid-derived suppressor cells (MDSC) and dendritic cell (DC) populations. Each can have protective roles, but has, by definition, been coopted by the tumor in patients with progressive disease. However, evidence demonstrates that myeloid immunosuppressive activities can be reversed in different ways, leading to enthusiasm for this therapeutic approach, both alone and in combination with potentially synergistic immunotherapeutic and other strategies. Here, we review the current understanding of myeloid cell immunosuppression of anti-tumor responses as well as potential targets, challenges, and developing means to reverse immunosuppression with various therapeutics and their status. Targets include myeloid cell colony stimulating factors (CSFs), insulin-like growth factor 1 (IGF1), several cytokines and chemokines, as well as CD40 activation and COX2 inhibition. Approaches in clinical development include antibodies, antisense RNA-based drugs, cell-based combinations, polarizing cytokines, and utilizing Macs as a platform for Chimeric Antigen Receptors (CAR)-based tumor targeting, like with CAR-T cells. To date, promising clinical results have been reported with several of these approaches." @default.
- W4214528097 created "2022-03-02" @default.
- W4214528097 creator A5013268190 @default.
- W4214528097 creator A5019377810 @default.
- W4214528097 creator A5045868163 @default.
- W4214528097 creator A5066158171 @default.
- W4214528097 creator A5086409602 @default.
- W4214528097 date "2022-02-18" @default.
- W4214528097 modified "2023-10-14" @default.
- W4214528097 title "Challenges and Opportunities for Immunotherapeutic Intervention against Myeloid Immunosuppression in Glioblastoma" @default.
- W4214528097 cites W1501247525 @default.
- W4214528097 cites W1703147773 @default.
- W4214528097 cites W1894485240 @default.
- W4214528097 cites W1945007559 @default.
- W4214528097 cites W1980485314 @default.
- W4214528097 cites W2008238182 @default.
- W4214528097 cites W2028459461 @default.
- W4214528097 cites W2039945589 @default.
- W4214528097 cites W2043184804 @default.
- W4214528097 cites W2046289497 @default.
- W4214528097 cites W2051003757 @default.
- W4214528097 cites W2116556497 @default.
- W4214528097 cites W2125493895 @default.
- W4214528097 cites W2134135742 @default.
- W4214528097 cites W2153232526 @default.
- W4214528097 cites W2248472864 @default.
- W4214528097 cites W2287464593 @default.
- W4214528097 cites W2288310939 @default.
- W4214528097 cites W2320521630 @default.
- W4214528097 cites W2342607195 @default.
- W4214528097 cites W2372854826 @default.
- W4214528097 cites W2515748600 @default.
- W4214528097 cites W2527350760 @default.
- W4214528097 cites W2548726144 @default.
- W4214528097 cites W2549204228 @default.
- W4214528097 cites W2555895139 @default.
- W4214528097 cites W2567155444 @default.
- W4214528097 cites W2594400638 @default.
- W4214528097 cites W2606914311 @default.
- W4214528097 cites W2611490456 @default.
- W4214528097 cites W2804367609 @default.
- W4214528097 cites W2896179230 @default.
- W4214528097 cites W2901390118 @default.
- W4214528097 cites W2903981326 @default.
- W4214528097 cites W2904714366 @default.
- W4214528097 cites W2913136103 @default.
- W4214528097 cites W2917960773 @default.
- W4214528097 cites W2919041616 @default.
- W4214528097 cites W2946162857 @default.
- W4214528097 cites W2957207031 @default.
- W4214528097 cites W2957546294 @default.
- W4214528097 cites W2978132006 @default.
- W4214528097 cites W2980625907 @default.
- W4214528097 cites W2980963406 @default.
- W4214528097 cites W2981127151 @default.
- W4214528097 cites W2982687009 @default.
- W4214528097 cites W2983134909 @default.
- W4214528097 cites W2994769926 @default.
- W4214528097 cites W3002145281 @default.
- W4214528097 cites W3004996004 @default.
- W4214528097 cites W3005258006 @default.
- W4214528097 cites W3005490880 @default.
- W4214528097 cites W3007410099 @default.
- W4214528097 cites W3011299571 @default.
- W4214528097 cites W3013195391 @default.
- W4214528097 cites W3014427389 @default.
- W4214528097 cites W3015530303 @default.
- W4214528097 cites W3015997773 @default.
- W4214528097 cites W3016132910 @default.
- W4214528097 cites W3028148036 @default.
- W4214528097 cites W3033978252 @default.
- W4214528097 cites W3035540747 @default.
- W4214528097 cites W3042272334 @default.
- W4214528097 cites W3043919067 @default.
- W4214528097 cites W3045921462 @default.
- W4214528097 cites W3047253843 @default.
- W4214528097 cites W3049387264 @default.
- W4214528097 cites W3088628777 @default.
- W4214528097 cites W3089833496 @default.
- W4214528097 cites W3090806704 @default.
- W4214528097 cites W3093221119 @default.
- W4214528097 cites W3094673097 @default.
- W4214528097 cites W3104085757 @default.
- W4214528097 cites W3105769299 @default.
- W4214528097 cites W3106079805 @default.
- W4214528097 cites W3108116652 @default.
- W4214528097 cites W3125945798 @default.
- W4214528097 cites W3135680734 @default.
- W4214528097 cites W3152385240 @default.
- W4214528097 cites W3168774386 @default.
- W4214528097 cites W3171365255 @default.
- W4214528097 cites W3194759535 @default.
- W4214528097 cites W3203304735 @default.
- W4214528097 cites W605176161 @default.
- W4214528097 cites W71124682 @default.
- W4214528097 cites W2031477804 @default.
- W4214528097 doi "https://doi.org/10.3390/jcm11041069" @default.
- W4214528097 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35207340" @default.